| __timestamp | Intra-Cellular Therapies, Inc. | Ligand Pharmaceuticals Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 21226345 | 9136000 |
| Thursday, January 1, 2015 | 139626 | 5807000 |
| Friday, January 1, 2016 | 93831530 | 5571000 |
| Sunday, January 1, 2017 | 79419009 | 5366000 |
| Monday, January 1, 2018 | 368673 | 6337000 |
| Tuesday, January 1, 2019 | 477121 | 11347000 |
| Wednesday, January 1, 2020 | 1895029 | 30419000 |
| Friday, January 1, 2021 | 8034589 | 62176000 |
| Saturday, January 1, 2022 | 20443000 | 52827000 |
| Sunday, January 1, 2023 | 33745000 | 35049000 |
In pursuit of knowledge
In the ever-evolving landscape of biopharmaceuticals, understanding cost structures is crucial. Over the past decade, Intra-Cellular Therapies, Inc. and Ligand Pharmaceuticals Incorporated have showcased intriguing trends in their cost of revenue. From 2014 to 2023, Intra-Cellular Therapies experienced a dramatic surge, with costs peaking in 2016 at nearly 90% higher than their 2014 levels. Meanwhile, Ligand Pharmaceuticals saw a more consistent rise, with a notable 500% increase from 2014 to 2021. This divergence highlights the varying strategies and market conditions faced by these companies. While Intra-Cellular's costs fluctuated, Ligand's steady climb suggests a more stable operational model. As the industry continues to innovate, these insights offer a glimpse into the financial strategies shaping the future of biopharmaceuticals.
Analyzing Cost of Revenue: Novo Nordisk A/S and Intra-Cellular Therapies, Inc.
Cost of Revenue: Key Insights for Merck & Co., Inc. and Intra-Cellular Therapies, Inc.
Comparing Cost of Revenue Efficiency: Sanofi vs Ligand Pharmaceuticals Incorporated
Cost of Revenue: Key Insights for Gilead Sciences, Inc. and Intra-Cellular Therapies, Inc.
GSK plc vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Teva Pharmaceutical Industries Limited and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Incyte Corporation and Ligand Pharmaceuticals Incorporated
Analyzing Cost of Revenue: Intra-Cellular Therapies, Inc. and Halozyme Therapeutics, Inc.
Intra-Cellular Therapies, Inc. vs MiMedx Group, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: PTC Therapeutics, Inc. vs Ligand Pharmaceuticals Incorporated
Comparing Cost of Revenue Efficiency: Perrigo Company plc vs Ligand Pharmaceuticals Incorporated
Cost of Revenue Comparison: Ligand Pharmaceuticals Incorporated vs Galapagos NV